ReviewWorld journal of gastroenterology2014
Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Serum miRNA-101 expression signature as non-invasive diagnostic biomarker for Hepatitis C virus-associated hepatocellular carcinoma in Egyptian patients.Scientific reports · 2025Article
- The Study of Performance of a Nanoribbon Biosensor, Sensitized with Aptamers and Antibodies, upon Detection of Core Antigen of Hepatitis C Virus.Micromachines · 2023Article
- Barriers and Facilitators to Hepatitis C Virus (HCV) Treatment for Aboriginal and Torres Strait Islander Peoples in Rural South Australia: A Service Providers' Perspective.International journal of environmental research and public health · 2023Article
- Article
- Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies.Sensors (Basel, Switzerland) · 2019Review
- Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities.Infection and drug resistance · 2017Article
- Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4.Journal of managed care & specialty pharmacy · 2016Article
- Assessment of fibrotic tissue and microvascular architecture by in-line phase-contrast imaging in a mouse model of liver fibrosis.European radiology · 2016Article
- Molecular characterization of Hepatitis C virus 3a in Peshawar.BMC infectious diseases · 2016Article
- Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India.PloS one · 2016Article
- Update on hepatitis B and C virus diagnosis.World journal of virology · 2015Review
- Circulating microRNA-196a as a candidate diagnostic biomarker for chronic hepatitis C.Molecular medicine reports · 2015Article
- Hepatitis C virus: Virology, diagnosis and treatment.World journal of hepatology · 2015Review
- Whole-organ and segmental stiffness measured with liver magnetic resonance elastography in healthy adults: significance of the region of interest.Abdominal imaging · 2015Article
- MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations.Biomarker insights · 2015Review
- Liver histology in asymptomatic Hepatitis-C virus positive blood donors.Pakistan journal of medical sciencesArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection represents a major public health issue. Hepatitis C can be cured by therapy, but many infected individuals are unaware of their status. Effective HCV screening, fast diagnosis and characterization, and hepatic fibrosis staging are highly relevant for controlling transmission, treating infected patients and, consequently, avoiding end-stage liver disease. Exposure to HCV can be determined with high sensitivity and specificity with currently available third generation serology assays. Additionally, the use of point-of-care tests can increase HCV screening opportunities. However, active HCV infection must be confirmed by direct diagnosis methods. Additionally, HCV genotyping is required prior to starting any treatment. Increasingly, high-volume clinical laboratories use different types of automated platforms, which have simplified sample processing, reduced hands-on-time, minimized contamination risks and human error and ensured full traceability of results. Significant advances have also been made in the field of fibrosis stage assessment with the development of non-invasive methods, such as imaging techniques and serum-based tests. However, no single test is currently available that is able to completely replace liver biopsy. This review focuses on approved commercial tools used to diagnose HCV infection and the recommended hepatic fibrosis staging tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.